NASDAQ:DNLI | Free Cash Flow | Denali Therapeutics Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2016-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$131.2M$2.47M-$133.67M
2025-12-31-$98.54M$1.52M-$100.06M
2025-03-31-$131.47M$5.08M-$136.55M
2024-12-31-$83.72M$5.09M-$88.81M
2024-03-31-$113.62M$2.15M-$115.77M
2023-12-31-$98.66M$2.24M-$100.89M
2023-03-31-$58.8M$2.79M-$61.59M
2022-12-31-$72.66M$4.85M-$77.51M
2022-03-31-$72.11M$4.04M-$76.15M
2021-12-31-$65.49M$3.05M-$68.55M
2021-03-31-$50.24M$2.8M-$53.04M
2020-12-31$513.92M$1.2M$512.72M209.37%
2020-03-31-$54.49M$879,000.00-$55.37M
2019-12-31-$47.64M$2.77M-$50.42M
2019-03-31-$30.32M$2.03M-$32.35M
2018-12-31$93.19M$1.44M$91.75M118.33%
2018-03-31$33.58M$537,000.00$33.04M
2017-12-31-$18.34M$1.07M-$19.41M
2017-03-31-$18.81M$868,000.00-$19.68M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$412.6M$9.5M-$422.1M
2024-12-31-$347.69M$15.91M-$363.61M
2023-12-31-$357.99M$12.94M-$370.93M
2022-12-31-$244.72M$17.83M-$262.55M
2021-12-31-$211.39M$8.5M-$219.89M
2020-12-31$416.15M$3.1M$413.06M580.66%
2019-12-31-$151.58M$17.92M-$169.5M
2018-12-31$50.12M$3.39M$46.72M
2017-12-31-$76.64M$2.88M-$79.51M
2016-12-31-$71.91M$6.13M-$78.04M